ClinicalTrials.Veeva

Menu

Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis

G

Ghent University Hospital (UZ)

Status and phase

Completed
Phase 2

Conditions

Cystic Fibrosis

Treatments

Drug: Giving DHA-rich supplement

Study type

Interventional

Funder types

Other

Identifiers

NCT00221546
2001/220

Details and patient eligibility

About

Investigation of the influence of giving DHA-rich supplement versus placebo on DHA-status and health evolution of patients with cystic fibrosis

Full description

Investigation of the influence of giving DHA-rich supplement versus placebo on DHA-status and health evolution of patients with cystic fibrosis

Enrollment

17 patients

Sex

All

Ages

6+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Delta F 508 homozygote
  • Stable clinical situation

Exclusion criteria

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

Triple Blind

17 participants in 2 patient groups, including a placebo group

DHA-rich supplement
Active Comparator group
Treatment:
Drug: Giving DHA-rich supplement
Placebo
Placebo Comparator group
Treatment:
Drug: Giving DHA-rich supplement

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems